aTyr Pharma Inc. (LIFE)
Symbol Info
Listed Symbol LIFE
Name aTyr Pharma Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $-
Latest Fiscal EPS $-16.08
Price Info
21 Day Moving Average $3.1232
21 Day EMA $3.263320
50 Day Moving Average $4.1302
50 Day EMA $4.054760
200 Day EMA $7.850960
200 Day Moving Average 6.486650
52 Week High $12.33
52 Week Low $2.76
52 Week Change $-65.322600
Alpha -0.078566
Beta 2.3080
Standard Deviation 0.215493
R2 0.153061
Periods 51
Share Information
10 Day Average Volume 82,441
20 Day Average Volume 73,437
30 Day Average Volume 152,728
50 Day Average Volume 131,464
Outstanding Shares 3,890,185
Float Shares 2,854,513
Percent Float 73.38%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 50
Institute Holdings Date 2019-07-31
Institute Bought Previous 3 Months 9,625,037
Institute Holdings Percent 47.000000
Institute Sold Previous 3 Months 114,905
Insider Holdings Date 2019-07-31
Insider Bought Previous 3 Months 12,502
Insider Holdings Percent 29.40%
Insider Sold Previous 3 Months 4,651
Insiders Shares Owned 1,035,672
Price Change
7 Day Price Change $0.0904999
7 Day Percent Change 3.10%
21 Day Price Change $-0.2000001
21 Day Percent Change -6.23%
30 Day Price Change $-0.6300001
30 Day Percent Change -17.31%
Month To Date Price Change $-0.5
Month To Date Percent -14.25%
90 Day Price Change $-3.052
90 Day Percent Change -50.35%
Quarter To Date $-2.1196
Quarter To Date Percent -41.32%
180 Day Price Change $-4.13
180 Day Percent Change -57.84%
200 Day Price Change $-4.2252
200 Day Percent Change -58.40%
Year To Date $-3.9298
Year To Date Percent -56.63%
Profile
Description aTyr Pharma Inc is a biotherapeutics company, engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology. It has discovered approximately 300 Physiocrines, a class of naturally occurring human proteins that it promotes homeostasis, a fundamental process of restoring stressed or diseased tissue to a healthier state. The company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component. Business activity is primarily conducted through the United States.
Details
Issue Type CS
Market Cap $11,709,457
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 3,890,185
CEO Sanjay S. Shukla
Employees 42
Last Audit UQ
Classification
CIK 0001339970
Industry Biotechnology
Sector Healthcare
NAICS Biological Product (except Diagnostic) Manufacturing(325414)
Info
Address 3545 John Hopkins Court
Suite Number 250
San Diego, CA 92121
Website https://www.atyrpharma.com
Facisimile +1 858 731-8394
Telephone +1 858 731-8389
Email investorrelations@atyrpharma.com
Key Ratios
Profitability
EBIT Margin -25,700
EBITDA Margin -24,590.4
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $94,000
Revenue Per Share $0.0242
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $-14,660,231
Price To Sales 124.568695
Price To Free Cash -0.5
PE High Last 5 Years -
Price To Book 0.4
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 0.4
Financial Strength
Total Debt To Equity 0.5
Int Coverage -
Current Ratio 3.9
Leverage Ratio 1.6
Quick Ratio 3.8
Long Term Debt To Capital 0.19
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -43.43
Return On Equity -67.25
Return On Capital -45.84
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
LIFE
aTyr Pharm..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.